Skip to content
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
BioTechGrid BioTechGrid
  • Home
  • Biotechnology
  • Medical Technology
  • Research
  • Genetics
  • Press Releases
    • Business Wire
    • GlobeNewswire
    • PRNewswire
  • Contact
  • Home
  • Biotechnology
  • MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial

MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial

August 10, 2026Posted inBiotechnology

MoonLake Immunotherapeutics announced positive phase 3 data of patients with psoriatic arthritis treated with its lead nanobody candidate, sonelokimab.

Post navigation

Previous Post
Jazz pays $820M to buy Actio, adding clinical-stage asset to orchestra of epilepsy therapies
Next Post
Molecular Residual Disease Testing Guides Care After EGFR-Mutated Lung Cancer Surgery molecular-residual-disease-testing-guides-care-after-egfr-mutated-lung-cancer-surgery

Recent Posts

  • Kidney Organoids Reveal Inflammatory Drivers of Diabetic Kidney Disease
  • Molecular Devices and STEMCELL Technologies Team Up to Automate Organoid Research
  • High-Grade Glioma Biology Varies by Age and Sex, Revealing Potential Treatment Targets
  • Sartorius and NIBRT Partner on Intensified and Continuous Bioprocessing Training Center
  • Mithrl Raises $20M to Expand Deployment of Its Biomedical World Model Across Biopharma

Archives

  • September 2026
  • August 2026
  • July 2026
  • June 2026
  • May 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • March 2024
  • January 2024
  • September 2023

Privacy Policy    Terms

Scroll to Top